MedWatch

ALK-director: Important strategic approval

With the expansion of the indication for their house dust mite pill, which now also covers the age range from 12-17 years, ALK gets access to a strategically important market segment.

Sunday, there was great rejoice at ALK when the allergy group announced that the company’s tablet-based vaccine against house dust mite allergy, Acarizax, had expanded its approval in 12 European countries so patients in the age of 12-17 years also have access to the treatment.

The pill was previously approved only for patients of more than 18 years old.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier